key: cord-0869985-ywytbawp
authors: Hanif, Muhammad; Haider, Muhammad Adnan; Xi, Qianlan; Ali, Mukarram Jamat; Ahmed, Muhammad Umer
title: A Review of the Risk Factors Associated With Poor Outcomes in Patients With Coronavirus Disease 2019
date: 2020-09-10
journal: Cureus
DOI: 10.7759/cureus.10350
sha: 1074ade33a68b5b85edcc83f546b951d9ac2a824
doc_id: 869985
cord_uid: ywytbawp

The global pandemic of coronavirus disease 2019 (COVID-19) and its rapid spread throughout the globe is of much concern. With little known about the peculiar virus and the changing mortality and morbidity, we attempt to review the risk factors associated with significant outcome. We conducted a review of the information available in medical journals published on COVID-19 risk factors associated with poor outcomes using PubMed®, Google Scholar, and material published online. The risk factors associated with poor outcome were kept in particular consideration. A total of 96 articles were thoroughly reviewed and analyzed so as to highlight the risk factors and the subsequent disease presentation that were present in patients with COVID-19. With little data available in this regard, emphasis and consideration of risk factors might help health care workers preclude the worst outcome. From the aforementioned search we can conclude that the most prevalent risk factors were reported to be hypertension followed by diabetes. In terms of mortality, age greater than 65 was the most significant risk factor. Among non-survivors, coagulation profile including d-dimers, prothrombin time, and inflammatory markers like erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum ferritin levels were very deranged. Much emphasis and consideration in relation to risk factors must be deliberated by health care workers so as to prevent severe outcomes and mitigate appropriate treatment modalities.

Hematologic 

It is well documented that advanced age is a predictor of mortality in patients with COVID-19, especially in those over 65 years of age. Yang et al. [3] reported that non-survivors were older than survivors (mean age=64·6 vs. 51·9, respectively) and were more likely to have chronic medical conditions, compared to survivors. Mehra et al. [4] found that age greater than 65 years was independently associated with an increased risk of in-hospital death (mortality of 10 [6] . A cohort study by Wang et al. [7] found that the mean age of the non-survivor group was remarkably higher than that of the survivor group. Wang et al. [8] , using a multivariate Cox proportional hazards regression model, showed that higher hazard ratios (HRs) for 15-day in-hospital death were associated with age >65 years. Nikpouraghdam et al. [9] , in Iran, also demonstrated that for each one-year increase in age, the odds of death increased by 5% (OR=1.05; 95% CI=1.04−1.06). Similarly, Leung et al. [10] found a significant high mortality ratio in COVID-19 patients aged ≥80 years. A quantitative evidence synthesis of clinical and laboratory factors in 852 patients, from Martins-Filho et al. [11] , showed an increased risk of in-hospital death in older patients.

Ruan et al. [12] found that there were significant differences in total white blood cell (WBC) counts, absolute values of lymphocytes, and platelets between the non-survivor and survivor groups, from a retrospective multicenter study in Wuhan, China. In comparison to nonsurvivors, there was significant higher lymphocyte count in survivors. In addition, Zhou et al. [13] found that the lymphocyte count was lowest on day seven after onset of illness and improved during hospitalization. Severe lymphopenia was also observed in non-survivors. The most influential marker of risk, according to Wang et al. [7] , was severe lymphopenia (<0.5 × 109/L), which was associated with higher mortality (HR=4.410) compared to patients with a lymphocyte count >0.5 × 109/L. Recently, a retrospective review of 323 hospitalized patients with COVID-19 in Wuhan, conducted by Hu et al. [5] , indicated that leukocytosis (>10 x109/L, p<0.001) and neutrophilia (>75 × 109/L, p<0.001) predicted unfavorable clinical outcomes. Similarly, in comparison to the survivor group, the non-survivor group was found to have high higher total WBC and neutrophil counts and lower lymphocyte counts as reported by Wang, et al. [8] . Liuet et al. [14] reported that there was an 8% higher risk of in-hospital mortality in patients with increased neutrophil-to-lymphocyte ratio (NLR), and patients in the highest NLR had a 15.04-fold higher risk of death. A meta-analysis from Henry et al. [15] also concluded that compared to survivors, non-survivors had significantly increased WBC counts and decreased lymphocyte and platelet counts. Quantitative evidence of clinical and laboratory factors in 852 patients, from Martins-Filho et al. [11] , also showed that survivors had lower levels of white blood cells and neutrophils. Therefore, increased total WBC counts, as well as increased NLR, decreased lymphocytes, and decreased platelet counts are independent risk factors of inhospital mortality in COVID-19 patients.

Ruan et al. [12] reported that total serum bilirubin, blood urea nitrogen (BUN), serum creatinine (Cr), myoglobin, and cardiac troponin were higher in non-survivors than survivors. In comparison to non-survivors, survivors were found to have low levels of cardiac troponin I, Cr, alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) as reported by Zhou et al. [13] . Serum albumin was lower in non-survivors than in survivors. High-sensitivity cardiac troponin I (>0.04 pg/mL, p=0.02) was reported to predict unfavorable clinical outcomes. Wang et al. [8] also demonstrated that Cr, BUN, ALT, aspartate aminotransferase (AST), LDH, and blood ammonia were significantly higher, whereas GFR and serum albumin were significantly lower in the non-survivor group. A meta-analysis by Henry et al. [15] also found that non-survivors had significantly elevated levels of cardiac troponin, liver enzymes (ALT and AST), and renal biomarkers (BUN, Cr) at presentation. Martins-Filho et al. [11] also found that non-survivor patients had increased levels of Cr, creatine kinase, high-sensitivity cardiac troponin I, LDH, and decreased levels of albumin. A meta-analysis of 2389 patients from Santoso et al. [16] demonstrated that cardiac injury was associated with higher mortality, which was defined as high-sensitivity cardiac troponin I>99thpercentile.

Inflammation is the body's innate immune response to various kinds of injury or insult and during this process a number of proteins are released into the bloodstream. Based on current clinical evidence, inflammatory biomarkers such as C-reactive protein (CRP), serum ferritin, procalcitonin, interleukins, and the erythrocyte sedimentation rate (ESR), play key roles as predictors in evaluating severity and mortality in COVID-19 patients [17] .

Rong-Hui et al. conducted a prospective study to evaluate the different predictors of mortality in 179 COVID-19 patients and concluded that non-survivors (n=21) had a higher level of Creactive protein (mean=86.4mg/L-1; range=39.9−105.5) than survivors (n=158) (mean=36.0 mg/L-1; range=19.3−91.0) with p=0.012 [18] .

In another study, Wang et al. evaluated the clinical course of 69 patients with COVID-19 and established that peripheral capillary oxygen saturation (SpO2) <90% was associated with a higher rate of erythrocyte sedimentation and CRP in comparison with patients with SpO2 ≥90% (p<0.001) [19] .

In a retrospective study, Fei Zhou et al. concluded that non-survivors had a higher level of interleukin 6 (IL-6) (mean=11·0 pg/mL; range=7·5-14·4) compared to survivors (mean=6·3 pg/mL; range=5·0-7·9; p<0.0001). They also found a higher level of serum ferritin (mean=1435.3 µg/L; range=728.9−2000.0) in non-survivors compared with survivors (mean=503.2 µg/L; range=264.0−921.5; p<0.0001) [13] . CRP was also reported to be higher (mean=38.9 mg/L; range=14.3−64.8) in unstable patients, compared to stable patients (mean: 10.6 mg/L; 1.9−33.1; p=0.024), in a study conducted by Lui et al. [20] .

In light of the above-mentioned studies, it is evident that high levels of CRP, ESR, IL-6, procalcitonin, and serum ferritin are associated with worse outcomes and increased mortality of patients with COVID-19.

Coagulation abnormalities, ranging from a small decrease in platelet count to disseminated intravascular coagulation, are associated with septicemia, as well as multisystem organ dysfunction syndrome (MODS) [21] . Many coagulative abnormalities have also been observed with SARS-CoV-2 infection, and have been proposed to be associated with increased mortality in COVID-19 patients.

Tang et al. concluded, from a retrospective study involving patients with COVID-19, that nonsurvivors had higher levels of D-dimers and fibrin degradation products (FDPs), and a raised prothrombin time, compared to survivors (p<0.001) [22] . In another retrospective study, Zhang et al. established that high levels of D-dimers are associated with increased mortality in patients with COVID-19 (p<0.001) [23] .

Similarly, Zhouet et al. reported that non-survivors had higher levels of D-dimers (mean=5·2μg/mL; range=1·5-21·1) than survivors (mean=0·6 μg/mL; range=0·3-1·0; p<0.0001) [13] .

It has been reported that pre-existing cerebrovascular disease, and stroke after diagnosis of COVID-19, are both predictors of mortality, which might be related to hypercoagulable state from clotting variables and platelet count [24, 25, 26] . Neurological manifestations including acute cerebrovascular diseases (5.7%), were found more in patients with severe condition with COVID-19 as reported Mao et al. [27] . A meta-analysis of observational studies from Tralhao et al. [28] reported that the incidence of acute stroke was 0.71% in pooled inpatients. Avula et al. [29] reported a series of four COVID-19 patients with acute stroke as a presenting symptom. Lodigiani et al. [30] found that 2.5% of patients admitted to the hospital with laboratory-proven COVID-19 were diagnosed with ischemic stroke. In a single-centered, retrospective, study conducted by Yang et al. [3] , the mortality rate was 61.5% by four weeks in 52 critically ill patients with COVID-19. From the review of Madjid et al. [31] , cerebrovascular diseases were found to be one of the most important factors associated with mortality in patients with COVID-19. A pooled analysis of published literature from Aggarwal et al. [32] , with a sample of 1829 confirmed COVID-19 patients, showed a ∼2.5-fold increase in odds of severe COVID-19 illness with a history of cerebrovascular disease. While a trend was observed, there was no statistically significant association between stroke and mortality in patients with COVID-19 infection.

Hypertension is the single most prevalent comorbid condition in COVID-19 patients, as shown in a study from China where 15% of the patients had hypertension [33] . Similarly, a nationwide survey, a meta-analysis, and a cross-sectional study from China showed that 16.9% [34] , 15.6%

[35], and 12.6% [36] of the COVID-19 patients had hypertension. However, two other studies showed that 30% [13] and 30.7% [37] had hypertension. These results are not surprising, as this proportion is quite similar to the general incidence of hypertension observed in the general Chinese population, which is 23.2% [38] .

Many studies have shown that hypertension is a risk factor associated with increased ICU admission and mortality in COVID-19 patients. Hypertension was found in higher proportion in patients with severe COVID-19 (23.7%) in comparison to non-severe (13.4%) as showed by Guan et al. [33] . Hypertension was also associated with poor composite outcomes included in this study (35.8% vs. 13.7%). Similarly, in another study, hypertension was more common in patients with severe disease (32.7% vs.12.6%) and hypertensive patients were found to have severe outcomes (invasive ventilations or death) in comparison to non-hypertensive (19.7% vs. 5.9%) [34] . Crude mortality was much more common in patients with hypertension (6.0%) than in patients without underlying comorbidities (0.9%) [36] . More severe COVID-19 manifestations, including acute respiratory distress syndrome (ARDS) and in-hospital death, are associated with hypertensive patients (21.3%) than with normotensive patients (6.5%, p<0.001) [37] . [39] . In an article stating that hypertension resulted in increased mortality in COVID-19 patients, 43% died and 28% survived (p=0.07) [12] . A metaanalysis showed that hypertension is more common in the critical/mortality group (OR=2.72; 95% CI=1.60−4.640; p=0.0002) [40] . Odds of death in COVID-19 patients have been reported to be increased 3.05-fold by having hypertension (95% CI=1.57−5.92; p=0.001) [13] .

Diabetes mellitus, characterized by hyperglycemia and insulin resistance, is a chronic inflammatory condition that leads to increased end products of glycosylation, inflammatory cytokine production, and oxidative stress, resulting in tissue damage and increased risk of infections, and leading to morbidity and mortality [41, 42, 43] . People with diabetes are prone to respiratory tract infections such as influenza and pneumonia [44] , and possibly COVID-19. Chronic inflammation, immune response impairment, increased coagulation activity, and (possibly) direct pancreatic damage caused by SARS-CoV-2 are potential underlying mechanisms [45] . [47] . Similarly, a significantly higher mortality (31% versus 14%; p=0.0051) was seen in patients with diabetes with COVID-19 than in those without diabetes in a retrospective cohort study conducted in Wuhan [13] .

In a retrospective, observational study, Yan et al. established that survival among those with DM was poorer, with COVID-19, compared to a non-DM group, with a hazard ratio (HR) of 1.53 (95% CI=1.02-2.30; p=0.041), after adjustment for age, sex, hypertension, cardiovascular disease, and cerebrovascular diseases [48] . Moreover, Zhu et al., in a retrospective study, found that all-cause mortality was 7.8% in DM patients with COVID-19 versus 2.7% in non-DM patients (HR=1.49; 95% CI=1.13-1.96; p=0.005). Additionally, all-cause mortality was lower (1.1%) in patients with tight glycemic control than in those with poorly controlled blood glucose levels (11.0%) [49] .

In conclusion, the existing literature is clearly showing increased mortality in diabetic patients compared to non-diabetic, especially in patients of advanced age. There is a need to develop novel ways to deliver healthcare to patients with DM using tele-health and for remote patient monitoring for tight glycemic control, without exposing them to unnecessary hazards.

From the aforementioned literature as summarized in Table 2 , we can conclude that the most prevalent risk factor is hypertension followed by diabetes. In terms of mortality, age greater than 65 was the most significant. Amongst non-survivors coagulation profile including ddimers, prothrombin time, and inflammatory markers like ESR, CRP, and serum ferritin levels were much deranged. Patients with diabetes mellitus, hypertension, cerebrovascular accidents, and age greater than 65 must be in particular managed at home in order to decrease unnecessary exposure at the hospital. From the above data we recommend that the patients with COVID-19 should initially be stratified and segregated on the basis of the above risk factors. Much emphasis and consideration in relation to risk factors must be deliberated by health care providers so as to prevent severe outcomes and mitigate appropriate treatment modalities.

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

A novel coronavirus outbreak of global health concern

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Cardiovascular disease, drug therapy, and mortality in Covid-19

Hospitalization and critical care of 109 decedents with COVID-19 pneumonia in Wuhan, China

Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan

15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study

Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: a single center study

Risk factors for predicting mortality in elderly patients with COVID-19: a review of clinical data in China

Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data

Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis

Hematological findings and complications of COVID-19

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Sepsis and thrombosis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

COVID-19 and cardiovascular disease

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Cardiovascular events after community-acquired pneumonia: a global perspective with systematic review and meta-analysis of observational studies

COVID-19 presenting as stroke

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Potential effects of coronaviruses on the cardiovascular system: a review

Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature

Clinical characteristics of coronavirus disease 2019 in China

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis

Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention: The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China

Status of hypertension in China: results from the China Hypertension Survey

COVID-19): a pooled analysis

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Infections in patients with diabetes mellitus: a review of pathogenesis

The role of inflammation in diabetes: Current concepts and future perspectives

Vascular complications of diabetes: mechanisms of injury and protective factors

New estimates of the burden of acute community-acquired infections among older people with diabetes mellitus: a retrospective cohort study using linked electronic health records

COVID-19 and diabetes: knowledge in progress

Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and metaregression

Clinical characteristics and outcomes of patients with severe covid-19 with diabetes

Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes